Bio-Gate AG Logo

Bio-Gate AG

Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.

BIG1 | F

Overview

Corporate Details

ISIN(s):
DE000BGAG981
LEI:
391200G5LKTIOTZOXP90
Country:
Germany
Address:
Neumeyerstr. 28-34, 90411 Nürnberg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bio-Gate AG is a leading provider of innovative technologies and customized solutions for health and hygiene. The company specializes in developing and applying antimicrobial and antiviral strategies to enhance materials and products. Its core markets include medical technology, where it provides coatings for medical implants and wound dressings to prevent infections. Bio-Gate's technologies are also utilized in derma-cosmetics, veterinary medicine (featuring its MicroSilver BG™ technology), and a range of industrial and consumer goods such as paints, plastics, and textiles, improving safety and adding value to end products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-29 18:39
Share Issue/Capital Change
Bio-Gate AG beschliet und platziert Barkapitalerhohung
German 6.3 KB
2025-09-30 15:07
Earnings Release
Bio-Gate veroffentlicht Halbjahreszahlen und bestatigt den Ausblick fur 2025
German 11.4 KB
2025-09-11 20:04
Share Issue/Capital Change
Bio-Gate AG beschliet und platziert Barkapitalerhohung
German 6.1 KB
2025-08-21 17:58
Director's Dealing
Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen
German 6.0 KB
2025-08-19 17:50
Capital/Financing Update
Bio-Gate AG: Bio-Gate AG beschliet Ausgabe einer Wandelschuldverschreibung unte…
German 6.2 KB
2025-08-12 17:40
Director's Dealing
Bio-Gate AG: Thomas Konradt, Zeichnung von Wandelschuldverschreibungen
German 5.9 KB
2025-07-31 21:17
Earnings Release
Bio-Gate veroffentlicht endgultige Zahlen 2024 und gibt positiven Ausblick fur …
German 13.0 KB
2025-06-03 21:13
Capital/Financing Update
Bio-Gate AG beschliet Ausgabe einer Wandelschuldverschreibung unter Ausschluss …
German 8.4 KB
2025-04-08 09:56
Regulatory News Service
Bio-Gate starkt in Nordamerika Prasenz fur den Absatz von Tierpflegeprodukten f…
German 12.9 KB
2025-04-08 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 38.0 KB
2025-02-27 11:09
Regulatory News Service
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhalt in klinisch…
German 14.2 KB
2025-02-26 11:09
Earnings Release
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhalt in klinisch…
German 14.2 KB
2025-02-21 09:30
Regulatory News Service
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB
2025-02-20 09:30
Earnings Release
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB
2025-02-20 09:30
Earnings Release
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB

Automate Your Workflow. Get a real-time feed of all Bio-Gate AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bio-Gate AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bio-Gate AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.